Buprenorphine and Inotuzumab Ozogamicin: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Inotuzumab Ozogamicin
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these medicines can affect the timing of your heartbeat. Buprenorphine (a pain or addiction medicine) and inotuzumab ozogamicin (a cancer treatment) can each stretch out a part of your heart's rhythm called the QT interval. When two medicines that do this are used together, the effect can add up, which in rare cases could lead to an irregular heartbeat.
To be clear, this concern is based on how these drugs work, not on a lot of real-world cases. The good news is your care team can manage this. Keep taking both as prescribed, and let them know if you feel dizzy, faint, or have a fluttering or racing heartbeat.
Effect: Additive risk of QT interval prolongation when buprenorphine is combined with inotuzumab ozogamicin. Both agents carry independent QT-prolonging potential; neither is a prodrug and this is a pharmacodynamic (additive), not a metabolic, interaction.
- Direction/magnitude: Additive QTc prolongation; magnitude with this specific pair not quantified.
- Onset: Unspecified.
- Evidence: Theoretical; risk of the combination not established.
- Management: Avoid concomitant use where possible. If co-administered, obtain baseline and periodic ECGs, correct hypokalemia/hypomagnesemia, and reassess in patients with bradycardia, CHF, digitalis therapy, or congenital/baseline QT prolongation.
What happens
An increased risk of QT interval prolongation
Interaction Deep Dive
Do not use buprenorphine together with medications that could extend the QT interval342. It remains unknown what risk arises from pairing buprenorphine with additional QT prolonging agents. When prescribing buprenorphine to patients who have risk factors, including hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia, these considerations should factor into clinical decision making 1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
Keep taking both medicines as prescribed unless your prescriber tells you otherwise. Because each can lengthen the QT interval, your care team may take extra steps:
- Where possible, they may consider whether both are truly needed together or whether an alternative fits better.
- They may check your heart rhythm with an ECG and monitor you more closely.
- They may check and correct your potassium and magnesium levels.
- They will weigh added risk if you have a slow heartbeat, heart failure, or a known long-QT history.
Tell your pharmacist or doctor right away if you feel faint, dizzy, or notice a fluttering or pounding heartbeat.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Buprenorphine and Inotuzumab Ozogamicin together?
Buprenorphine and inotuzumab ozogamicin can both prolong the QT interval, so using them together may add up that risk; this is a theoretical concern that your care team can manage with monitoring and by correcting electrolytes. Report any fainting, dizziness, or palpitations promptly. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Inotuzumab Ozogamicin interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Inotuzumab Ozogamicin interaction managed?
Keep taking both medicines as prescribed unless your prescriber tells you otherwise. Because each can lengthen the QT interval, your care team may take extra steps: Where possible, they may consider whether both are truly needed together or whether an alternative fits better. They may check your heart rhythm with an ECG and monitor you more closely. They may check and correct your potassium and ma… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Buprenorphine or Inotuzumab Ozogamicin need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (4)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: BUTRANS(R) transdermal system patch, buprenorphine transdermal system patch. Purdue Pharma L.P. (per FDA), Stamford, CT, 2016. DailyMed
- Product Information: BELBUCA(TM) buccal film, buprenorphine buccal film. Endo Pharmaceuticals Inc. (per FDA), Malvern, PA, 2016.
- Product Information: BUPRENEX(R) intravenous injection, intramuscular injection, buprenorphine HCl intravenous injection, intramuscular injection. Indivior Inc. (per DailyMed), Richmond, VA, 2016. DailyMed
Keep reading about Buprenorphine
Keep reading about Inotuzumab Ozogamicin
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist